Cargando…

Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections

Adoptive cell transfer (ACT) has long been at the forefront of the battle with cancer that began last century with the therapeutic application of tumor-infiltrating lymphocytes (TILs) against melanoma. The development of novel ACT approaches led researchers and clinicians to highly efficient technol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zmievskaya, Ekaterina, Valiullina, Aygul, Ganeeva, Irina, Petukhov, Alexey, Rizvanov, Albert, Bulatov, Emil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827151/ https://www.ncbi.nlm.nih.gov/pubmed/33435454 http://dx.doi.org/10.3390/biomedicines9010059

Ejemplares similares

Adoptive Immunotherapy beyond CAR T-Cells
por: Titov, Aleksei, et al.
Publicado: (2021)

Knowns and Unknowns about CAR-T Cell Dysfunction
por: Titov, Aleksei, et al.
Publicado: (2022)

Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
por: Titov, Aleksei, et al.
Publicado: (2020)

Evaluation of CAR-T Cells’ Cytotoxicity against Modified Solid Tumor Cell Lines
por: Valiullina, Aigul Kh., et al.
Publicado: (2023)

Сytotoxic effect of CAR-T cells against modified MCF-7 breast cancer cell line
por: Valiullina, Aigul Kh., et al.
Publicado: (2023)

Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies
por: Ganeeva, Irina, et al.
Publicado: (2022)

Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
por: Chasov, Vitaly, et al.
Publicado: (2021)

Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy
por: Chasov, Vitaly, et al.
Publicado: (2020)

Small Molecule Modulators of RING-Type E3 Ligases: MDM and Cullin Families as Targets
por: Bulatov, Emil, et al.
Publicado: (2018)

Neglected, yet significant role of FOXP1 in T-cell quiescence, differentiation and exhaustion
por: Kaminskiy, Yaroslav, et al.
Publicado: (2022)

The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
por: Titov, Aleksei, et al.
Publicado: (2018)

Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors
por: Bulatov, Emil, et al.
Publicado: (2018)

Novel approaches for the rational design of PROTAC linkers
por: Zagidullin, Almaz, et al.
Publicado: (2020)

Novel Isatin-based activator of p53 transcriptional functions in tumor cells
por: Mirgayazova, Regina, et al.
Publicado: (2019)

High Triglycerides Are Associated with Low Thrombocyte Counts and High VEGF in Nephropathia Epidemica
por: Martynova, Ekaterina V., et al.
Publicado: (2016)

Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
por: Mirgayazova, Regina, et al.
Publicado: (2020)

Biomarkers and Pathogenesis of Infectious and Autoimmune Diseases
por: Rizvanov, Albert A.
Publicado: (2022)

Urine-Derived Stem Cells: Applications in Regenerative and Predictive Medicine
por: Bento, Guida, et al.
Publicado: (2020)

Racing CARs to veterinary immuno-oncology
por: Cockey, James R., et al.
Publicado: (2023)

Innovation in BCMA CAR-T therapy: Building beyond the Model T
por: Banerjee, Rahul, et al.
Publicado: (2022)

CAR T cells for treating autoimmune diseases
por: Blache, Ulrich, et al.
Publicado: (2023)

The Interaction between Viral and Environmental Risk Factors in the Pathogenesis of Multiple Sclerosis
por: Tarlinton, Rachael Eugenie, et al.
Publicado: (2019)

The Past, Present, and Future of Non-Viral CAR T Cells
por: Moretti, Alex, et al.
Publicado: (2022)

CAR-T cells leave the comfort zone: current and future applications beyond cancer
por: Mazzi, Mariana Torres, et al.
Publicado: (2020)

Genetically Engineered Artificial Microvesicles Carrying Nerve Growth Factor Restrains the Progression of Autoimmune Encephalomyelitis in an Experimental Mouse Model
por: Alatrash, Reem, et al.
Publicado: (2023)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
por: Su, Christopher T., et al.
Publicado: (2021)

Beyond CAR T-Cell Therapy: Continued Monitoring and Management of Complications
por: Reiser, Victoria
Publicado: (2020)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
por: Iqbal, Madiha, et al.
Publicado: (2021)

Adipose-Derived Mesenchymal Stem Cell (MSC) Immortalization by Modulation of hTERT and TP53 Expression Levels
por: Rakhmatullina, Aigul R., et al.
Publicado: (2023)

Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021)

CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022)

Cutting-Edge CAR Engineering: Beyond T Cells
por: Chocarro, Luisa, et al.
Publicado: (2022)

The Application of Nanobody in CAR-T Therapy
por: Bao, Chaolemeng, et al.
Publicado: (2021)

CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option
por: Műzes, Györgyi, et al.
Publicado: (2023)

Chemical probes targeting epigenetic proteins: Applications beyond oncology
por: Ackloo, Suzanne, et al.
Publicado: (2017)

Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond
por: Theocharopoulos, Charalampos, et al.
Publicado: (2021)

Targeting Cullin–RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation
por: Bulatov, Emil, et al.
Publicado: (2015)

CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases
por: Seif, Michelle, et al.
Publicado: (2019)

CARs: a new approach for the treatment of autoimmune diseases
por: Sun, Yeting, et al.
Publicado: (2022)

The Akt pathway in oncology therapy and beyond (Review)
por: Nitulescu, George Mihai, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fnn97kcvv11ij71hne09o63ppr